0000000000454810

AUTHOR

Daniel Baeumer

showing 2 related works from this author

Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany

2021

Background. Comprehensive data on the epidemiology and comorbidities of chronic urticaria (CU) in Germany are either limited, or not contemporary. Objectives. To investigate the epidemiology of CU, overall comorbidities and healthcare resource utilized by patients with CU in Germany, using an anonymized statutory health insurance (SHI) database. Methods. Anonymized SHI claims research database of the Institute for Applied Health Research, Berlin [InGef] (01 January 2015-30 September 2018) was used to analyse insured individuals with a confirmed diagnosis of CU (ICD-10-GM codes). Twelve-month diagnosed prevalence and incidence, comorbidities (vs. atopic dermatitis and psoriasis), and healthc…

AdultMalemedicine.medical_specialtyUrticariaPopulation610Dermatologychronic urticariaGermanyPsoriasisInternal medicineHealth careEpidemiologyHumansMedicineddc:610ChildeducationChronic urticariaeducation.field_of_studybusiness.industryIncidence (epidemiology)healthcare utilizationAtopic dermatitisPatient Acceptance of Health Caremedicine.diseasecomorbidityInfectious DiseasesHealthcare utilizationChronic DiseaseFemaleepidemiologybusiness600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.

2018

BACKGROUND Previous reports indicate that patients with chronic spontaneous urticaria (CSU) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but it remains unclear if this has improved the management of these patients in clinical practice. OBJECTIVE To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 -antihistamine-refractory CSU in Germany. METHOD A World-wide Antihistamine-Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non-interventional study of CU in the real-world setting, supported by the manufacturer of omalizumab. Patie…

0301 basic medicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyMedizinDrug ResistanceOmalizumabOmalizumab03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineImmunology and AllergyHumansClinical significanceChronic UrticariaDisease burdenAngioedemabusiness.industryGuidelineDermatology Life Quality IndexMiddle Aged030104 developmental biology030228 respiratory systemHistamine H1 AntagonistsQuality of LifeAntihistamineFemalemedicine.symptombusinessmedicine.drugFollow-Up StudiesClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct